Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction

Drugs

Volumn 76, Issue 3, 2016, Pages 387-396

  McCormack, Paul L ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; ENALAPRIL; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; TETRAZOLE DERIVATIVE;

ANGIONEUROTIC EDEMA; ATRIAL FIBRILLATION; COUGHING; CREATININE BLOOD LEVEL; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FOLLOW UP; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL IMPAIRMENT; REVIEW; SIDE EFFECT; CHRONIC DISEASE; DOSE RESPONSE; DRUG ADMINISTRATION; HEART FUNCTION TEST; TREATMENT OUTCOME;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES; TREATMENT OUTCOME;

EID: 84958763999     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-016-0544-9     Document Type: Review

References (44)

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics - 2015 update: A report from the American Heart Association. Circulation. 2015;131(4):e29-322.
2. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;33(14):1787-847.
3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-327.
4. McMurray JJ. Neprilysin inhibition to treat heart failure: A tale of science, serendipity, and second chances. Eur J Heart Fail. 2015;17(3):242-7.
5. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920-6.
6. Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol. 2008;153(5):947-55.
7. Feng L, Karpinski PH, Sutton P, et al. LCZ696: A dual-acting sodium supramolecular complex. Tetrahedron Lett. 2012;53(3):275-6.
8. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401-14.
9. Novartis. Entresto™ (sacubitril and valsartan): US pescribing information. 2015. http://www.pharma.us.novartis.com. Accessed 24 Sep 2015.
10. European Medicines Agency. Entresto (sacubitril/valsartan): summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 12 Jan 2016.
11. US FDA. Diovan (valsartan): US prescribing information. 2015. http://www.accessdata.fda.gov. Accessed 24 Sep 2015.
12. Damman K, Andersen K, Belohlavek J, et al. Angiotensin receptor neprilysin inhibition and renal function in heart faulure: results from PARADIGM-HF [abstract no. 3301]. Eur Heart J. 2015;36(Suppl 1):545.
13. Gori M, Senni M, Claggett B, et al. Effect of LCZ696 on urinary albumin excretion and relation to outcomes in patients with heart failure [abstract no. 3302]. Eur Heart J. 2015;36(Suppl 1):545.
14. Gan L, Langenickel T, Petruck J, et al. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol. 2016;56(1):78-86
15. Ayalasomayajula S, Jordaan P, Pal P, et al. Assessment of pharmacokinetic drug interaction between LCZ696 and digoxin [abstract no. 449]. Hypertension. 2013;62(3, Suppl):449.
16. Ayalasomayajula S, Jordaan P, Pal P, et al. Assessment of drug interaction potential between LCZ696 and warfarin [abstract no. 448]. Hypertension. 2013;62(3, Suppl):448.
17. Gan L, Jiang X, Mendonza A, et al. Pharmacokinetic drug-drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel-ethinyl estradiol in healthy subjects. Clin Pharmacol Drug Dev. 2016;5(1):27-39.
18. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.
19. McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15(9):1062-73.
20. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61.
21. Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36(30):1990-7.
22. McMurray J, Jhund P, Gong J, et al. Prevention of progressive worsening of heart failure over time with the angiotensin-receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) [abstract no. 19363]. Circulation. 2015;132(Suppl 3):A19363.
23. Solomon SD, Packer M, Zile M, et al. Reduction in 30-day rehospitalization after discharge from a heart failure admission in patients receiving LCZ696 versus enalapril: PARADIGM-HF [abstract no. 17955]. Circulation. 2015;132(Suppl 3):A17955.
24. Jhund P, Claggett B, Solomon S, et al. Elevated high sensitivity troponin is associated with poorer outcomes in patients with heart failure and reduced by LCZ696 [abstract no. P214]. Eur Heart J. 2015;36(Suppl 1):22.
25. Zile MR, McMurray JJ, Packer M, et al. Prognostic implications of achieving an N-terminal pro-B-type natriuretic peptide level <1000 pg/ml in patients with heart failure: data from PARADIGM-HF [abstract no. 248]. J Card Fail. 2015;21(8):S106-7.
26. Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36(38):2576-84.
27. Solomon S, Packer M, Zile M, et al. The angiotensin receptor neprilysin inhibitor LCZ696 is effective across the spectrum of ejection fraction in heart failure with reduced ejection fraction [abstract no. 088]. J Card Fail. 2015;21(8):S45-6.
28. Bohm M, Refsgaard J, Ramires FJA, et al. Effect of the angiotensin receptor neprilysin inhibitor LCZ696 compared with enalapril according to systolic blood pressure in PARADIGM-HF [abstract no. P1794]. Eur J Heart Fail. 2015;17(Suppl 1):393.
29. Simpson J, Squire IB, Martinez F, et al. Effect of the angiotensin receptor neprilysin inhibitor LCZ696 compared with enalapril according to baseline risk in PARADIGM-HF [abstract no. P1416]. Eur J Heart Fail. 2015;17(Suppl 1):295-6.
30. Kristensen SL, Preiss D, Jhund PS, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016;9(1):e002560.
31. Claggett B, Packer M, McMurray JJV, et al. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med. 2015;373(23):2289-90.
32. Lewis E, Zile MR, Swedberg K, et al. Health-related quality of life outcomes in PARADIGM-HF [abstract no. 17912]. Circulation. 2015;132(Suppl 3):A17912.
33. McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015;36(7):434-9.
34. Cannon J, Boytsov S, Senni M, et al. Dementia-related adverse effects in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [abstract no. P242]. Eur J Heart Fail. 2015;17(Suppl 1):49-50.
35. Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005;280(45):37644-50.
36. Senni M, Reyes A, Majercak I, et al. Results of the TITRATION study: A 12-week, multicenter, randomized, double-blind, safety evaluation of a 3- versus 6-week up-titration regimen of LCZ696 in patients with HFrEF [abstract no. P1795]. Eur J Heart Fail. 2015;17(Suppl 1):393.
37. Senni M, Gogia H, Martinez Selles M, et al. Effect of baseline ACEI/ARB use on the safety and tolerability of up-titrating LCZ696 over 3 vs. 6 weeks: results from the TITRATION study [abstract no. 1281]. Eur J Heart Fail. 2015;17(Suppl 1):265-6.
38. Novartis. Swissmedic approves Novartis' new heart failure medicine Entresto™ [media release]. 18 Sep 2015. https://www.novartis.com/news. Accessed 2 Feb 2016.
39. Novartis Pharmaceuticals Canada Inc. Heart failure treatment ENTRESTO™ (LCZ696) shown to reduce the risk of cardiovascular death and hospitalization approved by Health Canada [media release]. 6 Oct 2015. http://www.novartis.ca/. Accessed 2 Feb 2016.
40. Novartis. Novartis' new heart failure medicine LCZ696, now called Entresto™, approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization [media release]. 7 Jul 2015. https://www.novartis.com. Accessed 2 Feb 2016.
41. Lillyblad MP. Dual angiotensin receptor and neprilysin inhibition in chronic systolic heart failure: understanding the new PARADIGM. Ann Pharmacother. 2015;49(11):1237-51.
42. McMurray JJ, Packer M, Solomon SD. Neprilysin inhibition for heart failure. N Engl J Med. 2014;371(24):2336-7.
43. California Technology Assessment Forum. CardioMEMS™ HF System (St. Jude Medical) and sacubitril/valsartan (Entresto™, Novartis) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks (draft report). 2015. http://ctaf.org/sites/default/files/u148/CHF-Draft-Report-091115.pdf. Accessed 18 Sep 2015.
44. The National Institute for Health and Care Excellence. NICE gives green light to innovative drug for common heart condition [media release]. 11 December 2015. http://www.nice.org.uk/news/press-and-media/nice-gives-green-light-to-innovative-drug-for-common-heart-condition. Accessed 2 Feb 2016.